Mirum Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Mirum Pharmaceuticals

07/05/2025 22:06

Mirum Pharmaceuticals Inc MIRM.OQ reported a quarterly adjusted loss of 30 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -54 cents.  The mean expectation of nine analysts for the quarter was for a loss of 33 cents per share. Wall Street expected results to range from -51 cents to -8 cents per share.

Revenue rose 61.2% to $111.59 million from a year ago; analysts expected $98.40 million.

Mirum Pharmaceuticals Inc's reported EPS for the quarter was a loss of 30 cents​.

The company reported a quarterly loss of $14.68 million.

Mirum Pharmaceuticals Inc shares had fallen by 9.0% this quarter and lost 0.8% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 25.2% in the last three months.​

In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Mirum Pharmaceuticals Inc is $68.00

This summary was machine generated from LSEG data May 7 at 09:06 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.33
-0.30
Beat
Dec. 31 2024
-0.24
-0.49
Missed
Sep. 30 2024
-0.45
-0.30
Beat
Jun. 30 2024
-0.47
-0.52
Missed